BCAR1 and breast cancer: While Ta et al. have found that overexpression of Cas confers resistance to Doxorubicin in breast cancer cells [5], we found that complete lack of Cas expression also reduces cellular responsiveness to Doxorubicin, although not to the same extent than cellular responsiveness to proteasome inhibitors.